Acurx Pharmaceuticals, Inc. — Form 8-K
Filed: October 29, 2026. The filing reports a governance change; it does not provide operating or financial results for a reporting period.
Business context and material change
On October 29, 2026, the Board approved and adopted an amendment to the Company’s Bylaws, effective that date. The amendment lowers the general quorum required to conduct business at stockholder meetings from a majority to one-third (33⅓%) of the voting power of outstanding shares entitled to vote, present in person, by remote communication where applicable, or by proxy. Exceptions apply where a different quorum is required by law, the Certificate of Incorporation, or the Bylaws.
Financial information and outlook
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating results. It contains no management outlook or financial commentary.
Investor verification points
- Review Exhibit 3.1, the full text of the bylaw amendment, for its exact terms and any exceptions.
- Confirm how the reduced quorum requirement may affect future stockholder meetings and voting.